News | November 01, 2022
Aptar Pharma completes Phase I global injectables expansion program
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
By 2025, Cipla plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry.
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
The initiative, with the support of MoHFW, will directly impact a population of more than 5.7 million that depend on the public health value chain across the 10 districts
Subscribe To Our Newsletter & Stay Updated
